Summary of Bill HR 6134
Bill 117 HR 6134, also known as the CBD Product Safety and Standardization Act of 2021, aims to regulate the production and sale of CBD products in the United States. The bill seeks to establish safety and quality standards for CBD products, ensuring that consumers are protected from harmful substances and misleading labeling.
Under this legislation, CBD products would be required to undergo testing by independent laboratories to verify their potency and purity. Manufacturers would also be required to provide detailed labeling information, including the CBD content, ingredients, and any potential side effects or warnings.
Additionally, the bill would establish a regulatory framework for the production and distribution of CBD products, including licensing requirements for manufacturers and retailers. This would help to ensure that only reputable companies are allowed to sell CBD products, reducing the risk of counterfeit or contaminated products entering the market.
Overall, the CBD Product Safety and Standardization Act of 2021 aims to promote consumer safety and confidence in the growing CBD industry by setting clear standards for product quality and transparency. By establishing these regulations, the bill seeks to protect consumers from potential harm and ensure that they have access to safe and effective CBD products.
Congressional Summary of HR 6134
CBD Product Safety and Standardization Act of 2021
This bill requires the Food and Drug Administration (FDA) to regulate food containing cannabidiol (CBD) derived from hemp as a food additive. (The FDA has determined that food containing added CBD cannot be sold in interstate commerce.)
Under this bill, in order to be sold, a food containing CBD derived from hemp must conform with current FDA requirements pertaining to food additives or be generally recognized as safe (GRAS). (Under current law, a food additive with the GRAS designation is not subject to FDA premarket review and approval requirements.)
In addition, such a food must comply with all other relevant FDA and labeling requirements.
Such a food shall be exempt from an existing provision that prohibits the sale of a food containing an additive that is (1) an FDA-approved drug or biological product, or (2) subject to certain clinical investigations.
The FDA must issue regulations pertaining to such foods that specify (1) the maximum amount of CBD derived from hemp per serving, (2) labeling and packaging requirements, and (3) any conditions for intended use.